The prospect for cytokine based therapeutic strategies in rheumatoid arthritis.
作者信息
Campion G V
机构信息
Synergen Europe Inc, The Hague, The Netherlands.
出版信息
Ann Rheum Dis. 1994 Aug;53(8):485-7. doi: 10.1136/ard.53.8.485.
Abstract
摘要
相似文献
1
The prospect for cytokine based therapeutic strategies in rheumatoid arthritis.类风湿关节炎中基于细胞因子的治疗策略前景。
Ann Rheum Dis. 1994 Aug;53(8):485-7. doi: 10.1136/ard.53.8.485.
2
The cytokine network in rheumatoid arthritis: definition of TNF alpha as a therapeutic target.类风湿关节炎中的细胞因子网络：将肿瘤坏死因子α定义为治疗靶点
J R Coll Physicians Lond. 1996 Nov-Dec;30(6):560-70.
3
[Experimental therapy of rheumatoid arthritis with antibodies to tumor necrosis factor].[用肿瘤坏死因子抗体对类风湿性关节炎进行实验性治疗]
Z Rheumatol. 1998 Oct;57(5):298-301. doi: 10.1007/s003930050115.
4
Cytokine therapy in rheumatoid arthritis.类风湿关节炎的细胞因子治疗
Lancet. 1996 Sep 21;348(9030):824-5. doi: 10.1016/s0140-6736(05)65243-9.
5
6
[New treatments for rheumatoid arthritis].[类风湿关节炎的新疗法]
Soins. 2004 Sep(688):37-8.
7
[Immunotherapy in rheumatoid arthritis; current status].[类风湿关节炎的免疫疗法；现状]
Ned Tijdschr Geneeskd. 1996 Jun 15;140(24):1255-9.
8
Treatments no longer in development for rheumatoid arthritis.不再用于类风湿关节炎治疗研发的疗法。
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii43-5. doi: 10.1136/ard.61.suppl_2.ii43.
9
Cytokines in rheumatoid arthritis: trials and tribulations.类风湿关节炎中的细胞因子：试验与磨难
Mol Med Today. 2000 Aug;6(8):315-23. doi: 10.1016/s1357-4310(00)01757-3.
10
Future use of biologic agents alone and in combination for the treatment of rheumatoid arthritis.生物制剂单独及联合用于类风湿关节炎治疗的未来应用。
Z Rheumatol. 1998 Feb;57(1):41-5. doi: 10.1007/s003930050058.
引用本文的文献
1
Disease-modifying antirheumatic drugs. Using their clinical pharmacological effects as a guide to their selection.改善病情抗风湿药。以其临床药理作用为指导进行选用。
Drugs. 1998 Sep;56(3):337-44. doi: 10.2165/00003495-199856030-00003.
2
Cytokine therapy in rheumatoid arthritis.类风湿关节炎的细胞因子疗法。
Ann Rheum Dis. 1994 Dec;53(12):840-1. doi: 10.1136/ard.53.12.840-b.
3
Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies.类风湿性病变中的肥大细胞、细胞因子和金属蛋白酶：双重免疫定位研究
Ann Rheum Dis. 1995 Nov;54(11):896-903. doi: 10.1136/ard.54.11.896.
本文引用的文献
1
An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles.人类肿瘤坏死因子α启动子区域内的一个等位基因多态性与HLA A1、B8和DR3等位基因密切相关。
J Exp Med. 1993 Feb 1;177(2):557-60. doi: 10.1084/jem.177.2.557.
2
Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment.用抗白细胞介素-1治疗改善已建立的小鼠胶原诱导性关节炎。
Clin Exp Immunol. 1994 Feb;95(2):237-43. doi: 10.1111/j.1365-2249.1994.tb06517.x.
3
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.用抗肿瘤坏死因子α嵌合单克隆抗体治疗类风湿性关节炎。
Arthritis Rheum. 1993 Dec;36(12):1681-90. doi: 10.1002/art.1780361206.
4
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.重组人白细胞介素1受体拮抗剂治疗脓毒症综合征患者。一项随机、双盲、安慰剂对照试验的结果。III期重组人白细胞介素1受体拮抗剂脓毒症综合征研究组
JAMA. 1994 Jun 15;271(23):1836-43.
5
Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis.滑液白细胞介素-1β与白细胞介素-1受体拮抗剂的平衡及莱姆关节炎的恢复
Lancet. 1993 Jan 16;341(8838):146-8. doi: 10.1016/0140-6736(93)90006-3.
6
A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha.系统性红斑狼疮与肿瘤坏死因子α之间的基因关联。
Eur J Immunol. 1994 Jan;24(1):191-5. doi: 10.1002/eji.1830240130.
7
8
9
Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection.内源性肿瘤坏死因子（恶病质素）对于宿主抵抗单核细胞增多性李斯特菌感染至关重要。
Infect Immun. 1988 Oct;56(10):2563-9. doi: 10.1128/iai.56.10.2563-2569.1988.
10
Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s).成纤维细胞和滑膜细胞产生前列腺素E2和胶原酶受尿源人白细胞介素1及抑制剂调控。
J Clin Invest. 1986 Oct;78(4):1120-4. doi: 10.1172/JCI112669.
Zotero 插件